Delivery Order SPE2DB20D1051-SPE2DB25FD7UP

Award Date 4/21/25
Potential Completion Date 4/22/25
Potential Value $3.8K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $9,601.35, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through...
This federal contract award, valued at $11,601.82, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order, with an ultimate completion date of July 29, 2024. This award is part of a larger Indefinite Delivery Contract (IDC) held by...
This federal contract award, valued at $6,293.45, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a delivery order under the larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, which is valued at $999,999,999 and runs...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract has a ceiling value of $10,209.05 and is a firm fixed-price delivery order, with an ultimate completion date of April 29, 2025. The contract is not set aside and is open to full and open competition....
This federal contract award, valued at $7,382.47, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of Myrbetriq ER 50 mg tablets, a medication used to treat overactive bladder. The contract is a firm fixed-price delivery order with an ultimate completion date of April 23, 2025. It is not designated as a set-aside contract, indicating open competition....
This federal contract award, valued at $9,163.98, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. This is a delivery order contract with a firm fixed price, and the ultimate completion date is August 9, 2023. The contract does not have a set-aside designation, indicating it was awarded through open competition....
This federal contract award, valued at $26,306.43, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for the supply of Myrbetriq ER 25 mg tablets, a medication used in the treatment of overactive bladder. The contract is not designated as a set-aside and represents an open competition. It is associated with a larger Indefinite Delivery Contract (IDC) held by...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 MG Tablet 90s, a medication for overactive bladder. The contract has a ceiling value of $4,554.41 and runs through March 27, 2025. It is a firm fixed-price delivery order contract with no set-aside designation, indicating open competition. AmerisourceBergen also holds a...
This federal contract award, valued at $3,420.83, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 50 mg tablets, a medication used for the treatment of overactive bladder. This is a firm-fixed-price delivery order contract with a period of performance through May 28, 2024. The award is part of a larger Indefinite Delivery Contract (IDC) that...
This federal contract award, valued at $11,069.56, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder. The contract has an ultimate completion date of March 7, 2025 and is structured as a Firm Fixed Price Delivery Order. It is not designated as a set-aside contract. AmerisourceBergen holds...
  • SPE2DB20D1051
    Indefinite Delivery Contract
  • SPE2DB20D1051-SPE2DB25FD7UP
    Delivery Order

This federal contract award, valued at $3,819.16, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract is for the delivery of Myrbetriq ER 25 mg tablets, a medication used to treat overactive bladder.

The contract is a delivery order under an existing Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA, designated as SPE2DX, with a total potential value of $999,999,999.00. This IDC serves as a comprehensive global pharmaceutical support vehicle for the DLA, U.S. Coast Guard, and other government agencies, allowing AmerisourceBergen to supply a wide range of pharmaceutical products and medical supplies to support military and veteran healthcare programs.

The contract does not have a set-aside designation, indicating open competition. The period of performance extends to April 2025.

Generated 7/21/25, 7:40 PM